logo-loader
viewImmuPharma PLC

Corporate Update

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-decoration:underline;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .br{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 53.95pt 90.0pt;}div.br{}p.dg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.de{font-family:"Calibri","sans-serif"; color:black}p.dh{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}span.dc{font-family:"Calibri","sans-serif";color:black}p.di{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.dj{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.dk{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white}p.dl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: justify} p.dm{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:72.0pt;text-align:justify; text-indent:-18.0pt;background:white}span.cw{font-size:10.0pt;line-height: 107%;font-family:Symbol;color:black}span.cv{font-size:10.0pt; line-height:107%;color:black}p.dn{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:108.0pt;text-align:justify; text-indent:-18.0pt;background:white}span.ct{font-size:10.0pt;line-height: 107%;font-family:"Courier New";color:black}span.cs{font-size: 10.0pt;line-height:107%;color:black}p.do{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:72.0pt;text-align:justify; text-indent:-18.0pt;background:white}p.dp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:72.0pt;text-align:justify; text-indent:-18.0pt;background:white}span.cq{font-family:Symbol; color:black}span.cp{font-size:10.0pt;line-height:107%; color:black} span.co{font-family:"Calibri","sans-serif"}p.dq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify;punctuation-wrap: hanging;text-autospace:ideograph-numeric ideograph-other}span.cm{font-family:"Calibri","sans-serif";color:#2D2D2D}span.cl{font-family:"Calibri","sans-serif"; color:#2D2D2D}span.ck{font-family: "Calibri","sans-serif";color:black}p.dr{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify}p.ds{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify;background: white}p.dt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; margin-bottom: 18.75pt; text-align: justify}p.du{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-div: italic; text-align: justify}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";} table.dv{width:467.6pt;margin-left:-5.25pt;border-collapse:collapse}td.bu{width:456.8pt;padding:0cm 5.4pt 0cm 5.4pt}p.dw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.dx{width:495.25pt;border-collapse:collapse}td.cd{width:281.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.dy{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.cb{width:192.3pt;padding:0cm 5.4pt 0cm 5.4pt}span.cc{font-family: "Calibri","sans-serif"}p.dz{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}p.ea{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other} span.eb{color:blue;font-family:"Calibri","sans-serif"; color:windowtext;text-decoration:none}p.ec{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify}p.ed{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-157.35pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}span.ee{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; text-decoration: none} /**/
RNS Number : 8100S
Immupharma PLC
14 March 2019
 

                                                                                                                                                                           14 March 2019

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

CORPORATE UPDATE

 

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on ongoing activities.

 

Key highlights:

 

·      Lupuzor™

Lupuzor™  'Managed Access Program'

Phase III 'open label extension'

·      Nucant (cancer) program: Clinical development collaboration with Incanthera Limited

·     Urelix technology

Lupuzor™

 

Lupuzor™ is the Company's late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial earlier in 2018, ImmuPharma continues to look at opportunities which over the longer term have the potential of bringing Lupuzor™ to market. As part of this strategy, the Company continues to engage with potential corporate partners as well as commencing a Managed Access Program for Lupuzor™.

Lupuzor™ Managed Access Program

 

ImmuPharma, together with its partner, is in the final preparations for its Managed Access Program ('MAP') being open to eligible patients in Europe. Further updates will be provided to the market in due course.

 

Lupuzor™ Extension Study

The Lupuzor™ open label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in Q2 2019.

Nucant Cancer Programme - Clinical Development Collaboration

As announced on 31 December 2018, the exclusivity period was extended to 31 March 2019. Discussions continue on this collaboration and an update will be provided in due course.

Ureka

 

ImmuPharma's subsidiary, Ureka Sarl ("Ureka") based in Bordeaux, is focusing on transforming peptides into efficient drugs for treatments in a number of therapeutic areas including Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis). Recently, a fundamental research paper on Ureka' proprietary technology 'Urelix™' was published in the peer reviewed research journal 'Nature Communications'.

 

ImmuPharma continues to look at all options regarding progression of Ureka's assets. This process is ongoing and further updates will be announced as appropriate.

 

 

Commenting on the announcement, Tim McCarthy, ImmuPharma's Chairman said: "We remain focused on creating long term value throughout our portfolio through initiatives including the Managed Access Program for Lupuzor™,  whilst the Company continues to engage with industry partners for potential collaboration opportunities on its projects."

 

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 207 152 4080

Tim McCarthy, Chairman

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDJJMLTMBABBTL

Quick facts: ImmuPharma PLC

Price: 7.85

Market: AIM
Market Cap: £13.14 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

on 11/9/19